Observational Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Crit Care Med. Dec 9, 2024; 13(4): 97631
Published online Dec 9, 2024. doi: 10.5492/wjccm.v13.i4.97631
Beyond conventional care: The therapeutic potential of hemoperfusion in severe COVID-19
John Vásquez-Torres, Ramses Dávila-Collado, Leyla Abdalah-Perez, Oscar Jarquin-Duran, José Santos Latino, Jorge Luis Espinoza
John Vásquez-Torres, Leyla Abdalah-Perez, Kidney and Hemodialysis Unit, Baptist Hospital of Nicaragua, Managua 2300, Nicaragua
Ramses Dávila-Collado, Oscar Jarquin-Duran, José Santos Latino, Emergency Medicine, Baptist Hospital of Nicaragua, Managua 2300, Nicaragua
Jorge Luis Espinoza, Faculty of Health Sciences, Kanazawa University, Kanazawa 920942, Japan
Co-first authors: John Vásquez-Torres and Ramses Dávila-Collado.
Author contributions: Vasquez-Torres J, Davila-Collado R contributed to data collection, data entry, and writing; Abdalah-Perez L contributed to data collection, data entry, and critical revision; Jarquin-Duran O contributed to data collection and data entry; Latino JS contributed to data collection and provided methodological support; Espinoza JL designed the research and contributed to conceptualization, writing, and review. Vasquez-Torres J and Davila-Collado R contributed equally to this work as co-first authors.
Institutional review board statement: Institutional Review Board approval was not required for this observational, retrospective study of routinely transmitted patient information.
Informed consent statement: Written informed consent for the report of this study was waived owing to the rapid emergence of cases during the peak of the pandemic.
Conflict-of-interest statement: There are no conflicts of interest to declare.
Data sharing statement: Data are available from the authors upon reasonable request.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jorge Luis Espinoza, MD, PhD, Professor, Faculty of Health Sciences, Kanazawa University, Kodatsuno 5-11-18, Kanazawa 920942, Japan. luis@staff.kanazawa-u.ac.jp
Received: June 4, 2024
Revised: August 26, 2024
Accepted: September 12, 2024
Published online: December 9, 2024
Processing time: 149 Days and 1.7 Hours
Core Tip

Core Tip: Hemoperfusion (HP) is an extracorporeal blood purification therapy that is increasingly being utilized in the intensive care unit. We show that HP improved respiratory and cardiovascular parameters and various inflammatory markers in a series of coronavirus disease 2019 patients in critical condition, in agreement with various reports from the literature. However, the absence of data from randomized controlled trials and a lack of consensus guidelines remain important issues for the utilization of HP in clinical practice.